Tag Archives: BIO

Orphan Drug Tax Credit is Crucial to Rare Disease R&D

medical_research

The term “rare disease” may be misleading: to be “rare” a disease must effect fewer than 200,000 people in the U.S., but there are over 7,000 rare diseases that have been identified. Taken together, that means that nearly 30 million Americans suffer from a rare disease or condition.  While innovative therapies have been developed for a variety of these diseases—including Sickle Cell Anemia, Gaucher Disease, and Huntington Disease—too many patients still lack treatment options. Developing Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

IP Sessions at the 2015 BIO International Convention

BIO International Convention

This year’s BIO International Convention will be host to educational sessions on the latest issues in the biotech IP sector.  The world’s largest biotechnology gathering, the convention offers attendees the chance to come together to hear, discuss, and learn about current issues affecting the biotech community. Here’s a look at the Intellectual Property Track at this year’s convention: Sessions* Intellectual Property Opening Plenary Antibody Therapeutics: May I Have Them All? The Impact of USPTO Inter Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,

BIO Chair Testifies Before Senate

BIO’s Chair and CEO of GlycoMimetics, Rachel King

BIO’s Chair and CEO of GlycoMimetics, Rachel King, testified before the Senate Committee on Small Business and Entrepreneurship today where she reinforced the need for patent protection incentives to encourage small business innovation. Ms. King also encouraged Congress to address weaknesses in the United States Patent and Trademark Office’s Inter Partes Review (IRP) system that allows abuses perpetrated against legitimate patent holders. Read her full testimony. You can read more about BIO’s position on patent Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

How Industry Rates Interactions with the FDA

shutterstock_26191726

Kicking off day one of the BIO CEO & Investor Conference in New York City, panelists in the ‘How Industry Rates Interactions with the FDA’ session brought attendees good news – communication with the FDA has improved overall. “The improvements we have seen in increased communications between FDA and sponsors is based on a continuous dialogue that has been established over the past several years in which BIO has been at the forefront,” said Jonathan Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Patently Biotech’s Top Articles of 2014

shutterstock_26191726

It’s been a whirlwind year for IP. From international trade negotiations, to revised PTO guidelines and dropping patent case stats, intellectual property is on the brain and in the news. Here are Patently Biotech’s top blog posts of 2014: TPP and IP: The Economic Benefits of a Pacific Trade Agreement Should the USPTO allow the patenting of living organisms? Gene Patent Questions Remain: USPTO Issues Examiner Guidelines Stopped at the Threshold: A New Study Reports Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,